J Pathol Transl Med.  2022 Nov;56(6):309-318. 10.4132/jptm.2022.08.30.

The application of high-throughput proteomics in cytopathology

• Nikas IP
• Ryu HS

• KMID: 2535850
• DOI: http://doi.org/10.4132/jptm.2022.08.30

Abstract

High-throughput genomics and transcriptomics are often applied in routine pathology practice to facilitate cancer diagnosis, assess prognosis, and predict response to therapy. However, the proteins rather than nucleic acids are the functional molecules defining the cellular phenotype in health and disease, whereas genomic profiling cannot evaluate processes such as the RNA splicing or posttranslational modifications and gene expression does not necessarily correlate with protein expression. Proteomic applications have recently advanced, overcoming the issue of low depth, inconsistency, and suboptimal accuracy, also enabling the use of minimal patient-derived specimens. This review aims to present the recent evidence regarding the use of high-throughput proteomics in both exfoliative and fine-needle aspiration cytology. Most studies used mass spectrometry, as this is associated with high depth, sensitivity, and specificity, and aimed to complement the traditional cytomorphologic diagnosis, in addition to identify novel cancer biomarkers. Examples of diagnostic dilemmas subjected to proteomic analysis included the evaluation of indeterminate thyroid nodules or prediction of lymph node metastasis from thyroid cancer, also the differentiation between benign and malignant serous effusions, pancreatic cancer from autoimmune pancreatitis, non-neoplastic from malignant biliary strictures, and benign from malignant salivary gland tumors. A few cancer biomarkers—related to diverse cancers involving the breast, thyroid, bladder, lung, serous cavities, salivary glands, and bone marrow—were also discovered. Notably, residual liquid-based cytology samples were suitable for satisfactory and reproducible proteomic analysis. Proteomics could become another routine pathology platform in the near future, potentially by using validated multi-omics protocols.

Keyword

Cytology; Fine-needle aspiration; Mass spectrometry; Cancer biomarker; Proteomics

Figure

• 

  Fig. 1. Example of a proteomic analysis workflow utilizing cytology specimens. HPLC, high-performance liquid chromatography; ESI, electrospray ionization.

Reference

References

1. Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif). 2013; 6:287–303.

2. Hou YC, Neidich JA, Duncavage EJ, Spencer DH, Schroeder MC. Clinical whole-genome sequencing in cancer diagnosis. Hum Mutat. 2022; 43:1519–30.

3. Hu T, Chitnis N, Monos D, Dinh A. Next-generation sequencing technologies: an overview. Hum Immunol. 2021; 82:801–11.

4. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015; 372:793–5.

5. Esagian SM, Grigoriadou G, Nikas IP, et al. Comparison of liquidbased to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. J Cancer Res Clin Oncol. 2020; 146:2051–66.

6. Grigoriadou G, Esagian SM, Ryu HS, Nikas IP. Molecular profiling of malignant pleural effusions with next generation sequencing (NGS): evidence that supports its role in cancer management. J Pers Med. 2020; 10:206.

7. Nikas IP, Mountzios G, Sydney GI, Ioakim KJ, Won JK, Papageorgis P. Evaluating pancreatic and biliary neoplasms with small biopsy-based next generation sequencing (NGS): doing more with less. Cancers (Basel). 2022; 14:397.

8. Tsamis KI, Sakkas H, Giannakis A, Ryu HS, Gartzonika C, Nikas IP. Evaluating infectious, neoplastic, immunological, and degenerative diseases of the central nervous system with cerebrospinal fluidbased next-generation sequencing. Mol Diagn Ther. 2021; 25:207–29.

9. Roy-Chowdhuri S, Pisapia P, Salto-Tellez M, et al. Invited reviewnext-generation sequencing: a modern tool in cytopathology. Virchows Arch. 2019; 475:3–11.

10. Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. Cell. 2016; 165:535–50.

11. Nagaraj N, Wisniewski JR, Geiger T, et al. Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol. 2011; 7:548.

12. Kageyama S, Isono T, Iwaki H, et al. Proteome research in urothelial carcinoma. Int J Urol. 2015; 22:621–8.

13. Banks RE, Dunn MJ, Hochstrasser DF, et al. Proteomics: new perspectives, new biomedical opportunities. Lancet. 2000; 356:1749–56.

14. Ramazi S, Allahverdi A, Zahiri J. Evaluation of post-translational modifications in histone proteins: a review on histone modification defects in developmental and neurological disorders. J Biosci. 2020; 45:135.

15. Doll S, Gnad F, Mann M. The case for proteomics and phosphoproteomics in personalized cancer medicine. Proteomics Clin Appl. 2019; 13:e1800113.

16. Menyhart O, Gyorffy B. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J. 2021; 19:949–60.

17. Singla D, Sangha MK. Multi-omic approaches to improve cancer diagnosis, prognosis, and therapeutics. In: Raza K, ed. Computational intelligence in oncology: applications in diagnosis, prognosis and therapeutics of cancers. Singapore: Springer Singapore;2022. p. 411–33.

18. Chandramouli K, Qian PY. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics. 2009; 2009:239204.

19. Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016; 537:347–55.

20. Choudhary C, Weinert BT, Nishida Y, Verdin E, Mann M. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol. 2014; 15:536–50.

21. Bekker-Jensen DB, Kelstrup CD, Batth TS, et al. An optimized shotgun strategy for the rapid generation of comprehensive human proteomes. Cell Syst. 2017; 4:587–99.

22. Zhu Y, Piehowski PD, Zhao R, et al. Nanodroplet processing platform for deep and quantitative proteome profiling of 10-100 mammalian cells. Nat Commun. 2018; 9:882.

23. Altelaar AF, Heck AJ. Trends in ultrasensitive proteomics. Curr Opin Chem Biol. 2012; 16:206–13.

24. Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis. 1998; 19:1853–61.

25. Blackstock WP, Weir MP. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 1999; 17:121–7.

26. Melton L. Protein arrays: proteomics in multiplex. Nature. 2004; 429:101–7.

27. Mueller LN, Rinner O, Schmidt A, et al. SuperHirn-a novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics. 2007; 7:3470–80.

28. Ghose A, Gullapalli SV, Chohan N, et al. Applications of proteomics in ovarian cancer: dawn of a new era. Proteomes. 2022; 10:16.

29. Hall DA, Ptacek J, Snyder M. Protein microarray technology. Mech Ageing Dev. 2007; 128:161–7.

30. Sreekumar A, Nyati MK, Varambally S, et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res. 2001; 61:7585–93.

31. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science. 2006; 312:212–7.

32. Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem. 2001; 70:437–73.

33. Alexander H, Stegner AL, Wagner-Mann C, Du Bois GC, Alexander S, Sauter ER. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res. 2004; 10:7500–10.

34. Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A. 2000; 97:9390–5.

35. Krause K, Jessnitzer B, Fuhrer D. Proteomics in thyroid tumor research. J Clin Endocrinol Metab. 2009; 94:2717–24.

36. Duncan M, DeMarco ML. MALDI-MS: Emerging roles in pathology and laboratory medicine. Clin Mass Spectrom. 2019; 13:1–4.

37. Kriegsmann J, Kriegsmann M, Casadonte R. MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics (review). Int J Oncol. 2015; 46:893–906.

38. Wright GL Jr. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn. 2002; 2:549–63.

39. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer. 2005; 114:791–6.

40. Leito I, Herodes K, Huopolainen M, et al. Towards the electrospray ionization mass spectrometry ionization efficiency scale of organic compounds. Rapid Commun Mass Spectrom. 2008; 22:379–84.

41. Chen Y, Quan L, Jia C, et al. Proteomics-based approach reveals the involvement of SERPINB9 in recurrent and relapsed multiple myeloma. J Proteome Res. 2021; 20:2673–86.

42. Pawlik TM, Fritsche H, Coombes KR, et al. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat. 2005; 89:149–57.

43. Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer. 2002; 86:1440–3.

44. George AL, Shaheed SU, Sutton CW. High-throughput proteomic profiling of nipple aspirate fluid from breast cancer patients compared with non-cancer controls: a step closer to clinical feasibility. J Clin Med. 2021; 10:2243.

45. Franzen B, Alexeyenko A, Kamali-Moghaddam M, et al. Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer. Mol Oncol. 2019; 13:376–91.

46. Fowler LJ, Lovell MO, Izbicka E. Fine-needle aspiration in PreservCyt: a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF. Mod Pathol. 2004; 17:1012–20.

47. Rapkiewicz A, Espina V, Zujewski JA, et al. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer. 2007; 111:173–84.

48. Pagni F, Mainini V, Garancini M, et al. Proteomics for the diagnosis of thyroid lesions: preliminary report. Cytopathology. 2015; 26:318–24.

49. Mainini V, Pagni F, Garancini M, et al. An alternative approach in endocrine pathology research: MALDI-IMS in papillary thyroid carcinoma. Endocr Pathol. 2013; 24:250–3.

50. Capitoli G, Piga I, Clerici F, et al. Analysis of Hashimoto’s thyroiditis on fine needle aspiration samples by MALDI-imaging. Biochim Biophys Acta Proteins Proteom. 2020; 1868:140481.

51. Pagni F, De Sio G, Garancini M, et al. Proteomics in thyroid cytopathology: relevance of MALDI-imaging in distinguishing malignant from benign lesions. Proteomics. 2016; 16:1775–84.

52. Capitoli G, Piga I, L'Imperio V, et al. Cytomolecular classification of thyroid nodules using fine-needle washes aspiration biopsies. Int J Mol Sci. 2022; 23:4156.

53. Capitoli G, Piga I, Galimberti S, et al. MALDI-MSI as a Complementary diagnostic tool in cytopathology: a pilot study for the characterization of thyroid nodules. Cancers (Basel). 2019; 11:1377.

54. Schwamborn K, Krieg RC, Uhlig S, Ikenberg H, Wellmann A. MALDI imaging as a specific diagnostic tool for routine cervical cytology specimens. Int J Mol Med. 2011; 27:417–21.

55. Schwamborn K, Weirich G, Steiger K, et al. Discerning the primary carcinoma in malignant peritoneal and pleural effusions using imaging mass spectrometry: a deasibility study. Proteomics Clin Appl. 2019; 13:e1800064.

56. Perzanowska A, Fatalska A, Wojtas G, et al. An MRM-based cytokeratin marker assay as a tool for cancer studies: application to lung cancer pleural effusions. Proteomics Clin Appl. 2018; 12:170084.

57. Li H, Tang Z, Zhu H, Ge H, Cui S, Jiang W. Proteomic study of benign and malignant pleural effusion. J Cancer Res Clin Oncol. 2016; 142:1191–200.

58. Inoue H, Eguchi A, Kobayashi Y, et al. Extracellular vesicles from pancreatic ductal adenocarcinoma endoscopic ultrasound-fine needle aspiration samples contain a protein barcode. J Hepatobiliary Pancreat Sci. 2022; 29:394–403.

59. Lee LS, Banks PA, Bellizzi AM, et al. Inflammatory protein profiling of pancreatic cyst fluid using EUS-FNA in tandem with cytokine microarray differentiates between branch duct IPMN and inflammatory cysts. J Immunol Methods. 2012; 382:142–9.

60. Navaneethan U, Lourdusamy V, Gk Venkatesh P, Willard B, Sanaka MR, Parsi MA. Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study. Gastroenterol Rep (Oxf). 2015; 3:136–43.

61. Seccia V, Navari E, Donadio E, et al. Proteomic investigation of malignant major salivary gland tumors. Head Neck Pathol. 2020; 14:362–73.

62. Pawlik TM, Hawke DH, Liu Y, et al. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotopecoded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer. 2006; 6:68.

63. Pavlou MP, Kulasingam V, Sauter ER, Kliethermes B, Diamandis EP. Nipple aspirate fluid proteome of healthy females and patients with breast cancer. Clin Chem. 2010; 56:848–55.

64. Noble JL, Dua RS, Coulton GR, Isacke CM, Gui GP. A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer. Eur J Cancer. 2007; 43:2315–20.

65. Giusti L, Iacconi P, Ciregia F, et al. Proteomic analysis of human thyroid fine needle aspiration fluid. J Endocrinol Invest. 2007; 30:865–9.

66. Giusti L, Iacconi P, Ciregia F, et al. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. J Proteome Res. 2008; 7:4079–88.

67. Ciregia F, Giusti L, Molinaro A, et al. Proteomic analysis of fineneedle aspiration in differential diagnosis of thyroid nodules. Transl Res. 2016; 176:81–94.

68. Ucal Y, Eravci M, Tokat F, Duren M, Ince U, Ozpinar A. Proteomic analysis reveals differential protein expression in variants of papillary thyroid carcinoma. EuPA Open Proteom. 2017; 17:1–6.

69. Lin P, Yao Z, Sun Y, et al. Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples. J Proteomics. 2019; 204:103414.

70. Park JH, Lee C, Han D, et al. Moesin (MSN) as a novel proteomebased diagnostic marker for early detection of invasive bladder urothelial carcinoma in liquid-based cytology. Cancers (Basel). 2020; 12:1018.

71. Yang N, Feng S, Shedden K, et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and labelfree quantification. Clin Cancer Res. 2011; 17:3349–59.

72. Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006; 7:230–40.

73. Lee H, Kim K, Woo J, et al. Quantitative proteomic analysis identifies AHNAK (neuroblast differentiation-associated protein AHNAK) as a novel candidate biomarker for bladder urothelial carcinoma diagnosis by liquid-based cytology. Mol Cell Proteomics. 2018; 17:1788–802.

74. Boylan KL, Afiuni-Zadeh S, Geller MA, et al. A feasibility study to identify proteins in the residual Pap test fluid of women with normal cytology by mass spectrometry-based proteomics. Clin Proteomics. 2014; 11:30.

75. Boylan KL, Afiuni-Zadeh S, Geller MA, Argenta PA, Griffin TJ, Skubitz APN. Evaluation of the potential of Pap test fluid and cervical swabs to serve as clinical diagnostic biospecimens for the detection of ovarian cancer by mass spectrometry-based proteomics. Clin Proteomics. 2021; 18:4.

76. Liu PJ, Chen CD, Wang CL, et al. In-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery. Mol Cell Proteomics. 2015; 14:917–32.

77. Li Y, Lian H, Jia Q, Wan Y. Proteome screening of pleural effusions identifies IL1A as a diagnostic biomarker for non-small cell lung cancer. Biochem Biophys Res Commun. 2015; 457:177–82.

78. Hegmans JP, Veltman JD, Fung ET, et al. Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDITOF MS. Technol Cancer Res Treat. 2009; 8:323–32.

79. Ucal Y, Tokat F, Duren M, Ince U, Ozpinar A. Peptide profile differences of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, encapsulated follicular variant, and classical papillary thyroid carcinoma: an application of matrix-assisted laser desorption/ionization mass spectrometry imaging. Thyroid. 2019; 29:1125–37.

80. Torres-Cabala C, Bibbo M, Panizo-Santos A, et al. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol. 2006; 50:518–28.